Premium
Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG‐1952
Author(s) -
Bassal Mylène,
La Mei K.,
Whitlock James A.,
Sather Harland N.,
Heerema Nyla A.,
Gay Paul S.,
Stork Linda C.
Publication year - 2005
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20193
Subject(s) - medicine , down syndrome , trisomy , lymphoblastic leukemia , cohort , toxicity , lymphoblast , chromosomal translocation , leukemia , gastroenterology , oncology , genetics , biology , cell culture , psychiatry , gene
Background Patients with Down syndrome (DS) and standard risk (SR) acute lymphoblastic leukemia (ALL‐DS) are reported to have inferior event free (EFS) and overall survival (OS) compared to patients without DS (ALL‐NDS). Procedure We compared the prevalence of favorable and unfavorable clinical and biologic features, toxicity and outcome within the ALL‐DS and ALL‐NDS cohorts of 2,174 eligible patients with SR‐ALL enrolled on CCG‐1952. Results Fifty‐nine patients (3%) had ALL‐DS. DS patients were less likely to have either favorable (hyperdiploidy, triple trisomy of chromosomes 4, 10, and 17, TEL‐AML1 rearrangement) or unfavorable (T‐cell ALL, hypodiploidy, adverse translocations) biologic features. Toxicity occurred significantly more often and number of days hospitalized was significantly greater in ALL‐DS than in ALL‐NDS. ALL‐DS patients had an inferior 4‐year EFS compared to the NDS cohort. However, EFS was equivalent when the comparison excluded ALL‐NDS with favorable biologic features. OS was significantly inferior for ALL‐DS. Conclusions The absence of favorable biologic features within ALL‐DS contributes to the difference in EFS previously observed between DS and NDS SR‐ALL cohorts. © 2004 Wiley‐Liss, Inc.